{
    "clinical_study": {
        "@rank": "168181", 
        "biospec_descr": {
            "textblock": "Whole Blood"
        }, 
        "biospec_retention": "Samples With DNA", 
        "brief_summary": {
            "textblock": "BAP1 serum germline, is a simple blood test in patients with nevi. This study aims to\n      examine the rate of germline BAP1 mutations in young patients diagnosed with choroidal nevi\n      to explore the role for this test as a screening tool in the future in this particular\n      patient population."
        }, 
        "brief_title": "BAP1 Testing in Instance Choroidal Nevi", 
        "completion_date": {
            "#text": "January 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Choroidal Nevi", 
        "condition_browse": {
            "mesh_term": [
                "Nevus", 
                "Nevus, Pigmented"
            ]
        }, 
        "detailed_description": {
            "textblock": "A germline BAP1 mutation predisposes a person to developing uveal melanoma and other\n      cancers. If a mutation is discovered, it changes the approach of managing the nevi. A\n      \"normal\" case of an choroidal nevus involves less frequent follow up visits and in this\n      time, the nevi could grow quickly. Closer follow up and more aggressive treatment could\n      preserve the patient's vision and potentially prevent micrometastatic spread. This new\n      screening technique will be able to extend the length and quality of life of patients with\n      more frequent targeted cancer screens."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        any person with choroidal nevi\n\n        Exclusion Criteria:\n\n        any persons under the age of 18 and over the age of 65"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "Patients age 18 and over and under age 65, diagnosed with choroidal nevi"
            }
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 15, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01925599", 
            "org_study_id": "BAP101"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Nevus", 
            "Choroidal Melanoma", 
            "BAP1 mutation"
        ], 
        "lastchanged_date": "March 4, 2014", 
        "location": {
            "contact": {
                "email": "leslie.kao@houstonretina.com", 
                "last_name": "Leslie Kao, BS", 
                "phone": "713-524-3434"
            }, 
            "contact_backup": {
                "email": "karri.schuetzle@houstonretina.com", 
                "last_name": "Karri Schuetzle", 
                "phone": "713-524-3434"
            }, 
            "facility": {
                "address": {
                    "city": "Houston", 
                    "country": "United States", 
                    "state": "Texas", 
                    "zip": "77030"
                }, 
                "name": "Retina Consultants of Houston"
            }, 
            "investigator": {
                "last_name": "Amy C Schefler, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_groups": "1", 
        "official_title": "Identification of Germline BAP1 Mutation in Young Patients With Choroidal Nevi", 
        "overall_contact": {
            "email": "acsmd@houstonretina.com", 
            "last_name": "Amy C Schefler, MD", 
            "phone": "713-524-3434"
        }, 
        "overall_contact_backup": {
            "email": "leslie.kao@houstonretina.com", 
            "last_name": "Lesli Kao, BS", 
            "phone": "713-524-3434"
        }, 
        "overall_official": {
            "affiliation": "Retina Consultants of Houston", 
            "last_name": "Amy C. Schefler, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Examine the rate of germline BAP1 mutations in young patients, diagnosed with choroidal nevi", 
            "safety_issue": "No", 
            "time_frame": "1 Year"
        }, 
        "reference": [
            {
                "PMID": "21704381", 
                "citation": "Singh AD, Turell ME, Topham AK. Uveal melanoma: trends in incidence, treatment, and survival. Ophthalmology. 2011 Sep;118(9):1881-5. doi: 10.1016/j.ophtha.2011.01.040. Epub 2011 Jun 24. Review."
            }, 
            {
                "PMID": "16154197", 
                "citation": "Singh AD, Kalyani P, Topham A. Estimating the risk of malignant transformation of a choroidal nevus. Ophthalmology. 2005 Oct;112(10):1784-9. Review."
            }, 
            {
                "PMID": "10546591", 
                "citation": "Jensen DE, Rauscher FJ 3rd. Defining biochemical functions for the BRCA1 tumor suppressor protein: analysis of the BRCA1 binding protein BAP1. Cancer Lett. 1999 Sep;143 Suppl 1:S13-7. Review."
            }, 
            {
                "PMID": "18757409", 
                "citation": "Ventii KH, Devi NS, Friedrich KL, Chernova TA, Tighiouart M, Van Meir EG, Wilkinson KD. BRCA1-associated protein-1 is a tumor suppressor that requires deubiquitinating activity and nuclear localization. Cancer Res. 2008 Sep 1;68(17):6953-62. doi: 10.1158/0008-5472.CAN-08-0365."
            }, 
            {
                "PMID": "23915344", 
                "citation": "Matatall KA, Agapova OA, Onken MD, Worley LA, Bowcock AM, Harbour JW. BAP1 deficiency causes loss of melanocytic cell identity in uveal melanoma. BMC Cancer. 2013 Aug 5;13(1):371. [Epub ahead of print]"
            }, 
            {
                "PMID": "21941004", 
                "citation": "Abdel-Rahman MH, Pilarski R, Cebulla CM, Massengill JB, Christopher BN, Boru G, Hovland P, Davidorf FH. Germline BAP1 mutation predisposes to uveal melanoma, lung adenocarcinoma, meningioma, and other cancers. J Med Genet. 2011 Dec;48(12):856-9. doi: 10.1136/jmedgenet-2011-100156. Epub 2011 Sep 22."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01925599"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Greater Houston Retina Research", 
            "investigator_full_name": "Amy C Schefler, MD", 
            "investigator_title": "Director of Ophthalmic Oncology", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "source": "Greater Houston Retina Research", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Amy C Schefler, MD", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Observational Model: Case-Only, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "March 2014"
    }
}